Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Decitabine Intensified Conditioning for High Risk Hematological Malignancies
NCT04582604Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib, decitabine in acute leukemia, myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), chronic myelomonocytic leukemia (CMML), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
ruxolitinibdecitabine
03
Conditions
acute leukemiamyelodysplastic syndrome (MDS)myeloproliferative neoplasm (MPN)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04582604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04582604.